Qiagen N.V.

NYSE:QGEN Stock Report

Market Cap: US$9.9b

Qiagen Past Earnings Performance

Past criteria checks 1/6

Qiagen has been growing earnings at an average annual rate of 13.9%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 4.1% per year. Qiagen's return on equity is 2.6%, and it has net margins of 4.7%.

Key information

13.9%

Earnings growth rate

13.9%

EPS growth rate

Life Sciences Industry Growth21.5%
Revenue growth rate4.1%
Return on equity2.6%
Net Margin4.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Qiagen (NYSE:QGEN) Seems To Use Debt Rather Sparingly

Dec 10
Qiagen (NYSE:QGEN) Seems To Use Debt Rather Sparingly

Some Confidence Is Lacking In Qiagen N.V.'s (NYSE:QGEN) P/S

Oct 11
Some Confidence Is Lacking In Qiagen N.V.'s (NYSE:QGEN) P/S

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued

Sep 24
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued

With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For

May 21
With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For

Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

May 03
Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly

Mar 20
Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly

Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Feb 13
Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

Jan 23
Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold

Sep 09

Qiagen: Major Asset Growth Needed In Post-Covid World

Jun 22

Qiagen: Strong Q4, Derisked Portfolio, Fairly Valued

Feb 14

Qiagen Non-GAAP EPS of $0.53, revenue of $498M, FY23 guidance initiated

Feb 07

Qiagen, Helix partner to advance NGS companion diagnostics in hereditary diseases

Jan 06

Qiagen's test gets FDA nod for companion diagnostic to Mirati's cancer drug Krazati

Dec 13

Qiagen Non-GAAP EPS of $0.53 beats by $0.08, revenue of $500M beats by $17.91M

Nov 07

Qiagen stock down after BHF downgrades rating to Neutral

Oct 10

Revenue & Expenses Breakdown

How Qiagen makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NYSE:QGEN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,96693569191
30 Jun 241,94073568194
31 Mar 241,939337570195
31 Dec 231,965341579199
30 Sep 231,954332587197
30 Jun 231,978337593198
31 Mar 231,999353599198
31 Dec 222,142423604190
30 Sep 222,226488618178
30 Jun 222,261539616177
31 Mar 222,313563606180
31 Dec 212,252513584190
30 Sep 212,240311604184
30 Jun 212,190480572182
31 Mar 212,065449549162
31 Dec 201,870359525149
30 Sep 201,713191522137
30 Jun 201,61214517142
31 Mar 201,550-31530151
31 Dec 191,526-41530157
30 Sep 191,516-25502164
30 Jun 191,511196492164
31 Mar 191,507188508163
31 Dec 181,502190497162
30 Sep 181,49690476162
30 Jun 181,48278474158
31 Mar 181,45355466157
31 Dec 171,41840478154
30 Sep 171,38789467145
30 Jun 171,36275480143
31 Mar 171,34782480147
31 Dec 161,33880470150
30 Sep 161,320123485157
30 Jun 161,296123471157
31 Mar 161,281126450148
31 Dec 151,281130445147
30 Sep 151,293104475151
30 Jun 151,315105484157
31 Mar 151,326113487162
31 Dec 141,345116490164
30 Sep 141,345151487163
30 Jun 141,331157487156
31 Mar 141,31572487152
31 Dec 131,30269486146

Quality Earnings: QGEN has a large one-off loss of $387.2M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: QGEN's current net profit margins (4.7%) are lower than last year (17%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: QGEN has become profitable over the past 5 years, growing earnings by 13.9% per year.

Accelerating Growth: QGEN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: QGEN had negative earnings growth (-72%) over the past year, making it difficult to compare to the Life Sciences industry average (-4.7%).

Return on Equity

High ROE: QGEN's Return on Equity (2.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:05
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Qiagen N.V. is covered by 63 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Daniel OwczarskiAvondale Partners
Catherine Ramsey SchulteBaird
Carla BänzigerBank Vontobel AG